148 related articles for article (PubMed ID: 35820351)
1. A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors.
Dong J; Pervaiz W; Tayyab B; Li D; Kang L; Zhang H; Gong H; Ma X; Li J; Agboyibor C; Bi Y; Liu H
Eur J Med Chem; 2022 Oct; 240():114564. PubMed ID: 35820351
[TBL] [Abstract][Full Text] [Related]
2. Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers.
Lee DY; Salahuddin T; Iqbal J
Curr Oncol; 2023 Feb; 30(2):2127-2143. PubMed ID: 36826125
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of targeting LSD1/ KDM1A in cancers.
Zhang X; Wang X; Wu T; Yin W; Yan J; Sun Y; Zhao D
Pharmacol Res; 2022 Jan; 175():105958. PubMed ID: 34718134
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
5. Exploring the potential of histone demethylase inhibition in multi-therapeutic approaches for cancer treatment.
Li D; Liang H; Wei Y; Xiao H; Peng X; Pan W
Eur J Med Chem; 2024 Jan; 264():115999. PubMed ID: 38043489
[TBL] [Abstract][Full Text] [Related]
6. Advances toward LSD1 inhibitors for cancer therapy.
Fu X; Zhang P; Yu B
Future Med Chem; 2017 Jul; 9(11):1227-1242. PubMed ID: 28722477
[TBL] [Abstract][Full Text] [Related]
7. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
8. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.
Lim S; Janzer A; Becker A; Zimmer A; Schüle R; Buettner R; Kirfel J
Carcinogenesis; 2010 Mar; 31(3):512-20. PubMed ID: 20042638
[TBL] [Abstract][Full Text] [Related]
9. High expression of the histone demethylase LSD1 associates with cancer cell proliferation and unfavorable prognosis in tongue cancer.
Yuan C; Li Z; Qi B; Zhang W; Cheng J; Wang Y
J Oral Pathol Med; 2015 Feb; 44(2):159-65. PubMed ID: 25040359
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
[TBL] [Abstract][Full Text] [Related]
11. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.
Schulte JH; Lim S; Schramm A; Friedrichs N; Koster J; Versteeg R; Ora I; Pajtler K; Klein-Hitpass L; Kuhfittig-Kulle S; Metzger E; Schüle R; Eggert A; Buettner R; Kirfel J
Cancer Res; 2009 Mar; 69(5):2065-71. PubMed ID: 19223552
[TBL] [Abstract][Full Text] [Related]
12. Histone Demethylase LSD1 Regulates Kidney Cancer Progression by Modulating Androgen Receptor Activity.
Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kwak C; Kim HH
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32847068
[TBL] [Abstract][Full Text] [Related]
13. LSD1 inhibitors: a patent review (2010-2015).
Stazi G; Zwergel C; Valente S; Mai A
Expert Opin Ther Pat; 2016 May; 26(5):565-80. PubMed ID: 27019002
[TBL] [Abstract][Full Text] [Related]
14. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
[TBL] [Abstract][Full Text] [Related]
15. Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma.
Lee C; Rudneva VA; Erkek S; Zapatka M; Chau LQ; Tacheva-Grigorova SK; Garancher A; Rusert JM; Aksoy O; Lea R; Mohammad HP; Wang J; Weiss WA; Grimes HL; Pfister SM; Northcott PA; Wechsler-Reya RJ
Nat Commun; 2019 Jan; 10(1):332. PubMed ID: 30659187
[TBL] [Abstract][Full Text] [Related]
16. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
Song Y; Zhang H; Yang X; Shi Y; Yu B
Eur J Med Chem; 2022 Jan; 228():114042. PubMed ID: 34915312
[TBL] [Abstract][Full Text] [Related]
17. CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression.
Hsu HC; Liu YS; Tseng KC; Yang TS; Yeh CY; You JF; Hung HY; Chen SJ; Chen HC
J Cancer Res Clin Oncol; 2015 Jan; 141(1):11-21. PubMed ID: 25060070
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
19. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
Murray-Stewart T; Woster PM; Casero RA
Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML.
Nicosia L; Boffo FL; Ceccacci E; Conforti F; Pallavicini I; Bedin F; Ravasio R; Massignani E; Somervaille TCP; Minucci S; Bonaldi T
Oncogene; 2022 Feb; 41(6):878-894. PubMed ID: 34862459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
